Soleus Goes Activist

The life sciences hedge fund has targeted a biopharmaceuticals company that specializes in HIV medicines.

Art_Soleus_1130 (1).jpg

Illustration by II

A life sciences hedge fund has gone activist on one of its smaller holdings.

Soleus Capital Management converted its 13G filing, which suggests a passive investment, to a 13D document for Montreal-based Theratechnologies, a biopharmaceuticals company focused on the development and commercialization of innovative therapies.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.